In my post on this blog of June 17th, I speculated that the positive comments by the Supreme Court in the Myriad decision about the patent-eligibility of claims directed to new applications of natural products (like the BRCA genes) would be available to temper the damage caused by the Court’s holding that isolated genes are [...]
The post Myriad Brings Out Its “Reserve Claims” To Challenge Ambry appeared first on Biotechnology Patent Law Blog | Patents4Life by Warren Woessner.